prostate cancer (mCRPC)
Oncology · 2005–2025
32decisions
12medicines
12carried consumer input
194individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| abiraterone acetate and prednisolone Treatment of patients with metastatic castration resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen… | Jul 2025 | Recommended with restriction | input received Rare Cancers Australia |
| talazoparib First-line treatment of metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 pathogenic variants in combination with enzalutamide, in patients… | Jul 2024 | Recommended with restriction | unclear |
| talazoparib First-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA1/2 pathogenic variants who have not received prior… | Mar 2024 | Not recommended | input received Rare Cancers Australia · Medical Oncology Group |
| olaparib First-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA1/2 pathogenic variants who have not received prior novel… | Nov 2023 | Not recommended | 10 individuals Medical Oncology Group · Prostate Cancer Foundation · Blue Mountains Prostate Cancer Support Group · Bega Valley Prostate Cancer Support Group · South Eastern Prostate Cancer Support Group · Prostate Cancer Support Group · Mens Cancer Support Group · Bayside Kingston Prostate Cancer Support Group · Cancer Support Group · Lakes Entrance Prostate Cancer Support Group · Grafton Prostate Cancer Support Group · Support Group |
| abiraterone acetate and methylprednisolone Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The co-pack comprises abiraterone acetate tablets in a fine particle… | Mar 2022 | Not recommended | none received |
| cabazitaxel Treatment of castration resistant metastatic carcinoma of the prostate in patients who have failed docetaxel treatment, in combination with prednisone or… | Mar 2022 | Recommended with restriction | none received |
| abiraterone acetate and methylprednisolone Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen… | Nov 2022 | Recommended with restriction | input received |
| darolutamide Treatment of patients with castration-resistant prostate cancer (CRPC), specifically non-metastatic CRPC (m0CRPC) with a prostate-specific antigen doubling… | Jul 2021 | Recommended | 7 individuals Prostate Cancer Foundation · Prostate Cancer Support Group · Bathurst District Prostate Cancer Support Group · South Eastern Prostate Cancer Support Group · District Prostate Cancer Support Group · Geelong Prostate Support Group · Blue Mountains Prostate Cancer Support Group · Medical Oncology Group |
| abiraterone acetate; enzalutamide Treatment of metastatic castration-resistant prostate cancer (mCRPC) prior to receiving docetaxel, removing the previous requirement for patients to have… | Mar 2021 | Recommended | no section in document |
| cabazitaxel Treatment of patients with castration resistant metastatic carcinoma of the prostate previously treated with a docetaxel-containing regimen, in combination… | Mar 2021 | Recommended | none received |
| olaparib Treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with pathogenic or likely pathogenic BRCA1/2 gene variants who have progressed… | Mar 2021 | Not recommended | input received Prostate Cancer Foundation · Medical Oncology Group |
| olaparib Treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA1/2 pathogenic gene variants who have progressed following prior… | Nov 2021 | Recommended with restriction | input received Support Group · Prostate Heidelberg Cancer Support Group · Blue Mountains Prostate Cancer Support Group · Prostate Cancer Foundation · Medical Oncology Group |
| abiraterone acetate Metastatic castration-resistant carcinoma of the prostate in combination with a corticosteroid. | Jul 2017 | Recommended with restriction | none received |
| enzalutamide Treatment of metastatic castration-resistant prostate cancer (mCRPC) prior to docetaxel in patients who have failed or are unsuitable for docetaxel treatment. | Jul 2017 | Deferred | unclear |
| abiraterone acetate Treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with corticosteroids, in patients who have failed or are unsuitable for… | Mar 2017 | Recommended with restriction | none received |
| docetaxel Treatment of androgen-independent (castrate-resistant) metastatic prostate cancer, and other indications for which docetaxel was previously listed on the PBS. | Mar 2017 | Recommended | no section in document |
| enzalutamide Treatment of metastatic castration-resistant prostate cancer (mCRPC) in chemotherapy-naïve patients prior to docetaxel. | Mar 2017 | Deferred | 90 individuals Medical Oncology Group |
| radium (223Ra) dichloride Treatment of castration-resistant metastatic carcinoma of the prostate with symptomatic bone metastases in patients who have failed or are unsuitable for… | Nov 2017 | Recommended with restriction | 9 individuals Prostate Cancer Foundation · Prostate Heidelberg Cancer Supporters Group · Medical Oncology Group |
| enzalutamide Treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have not had prior docetaxel, specifically in asymptomatic or mildly… | Nov 2015 | Not recommended | 12 individuals Medical Oncology Group |
| abiraterone acetate Treatment of metastatic castration-resistant prostate cancer (mCRPC) in asymptomatic or mildly symptomatic patients who have progressed following androgen… | Jul 2014 | Not recommended | 66 individuals Medical Oncology Group |
| enzalutamide Treatment of metastatic castration-resistant prostate cancer (mCRPC) after treatment failure with docetaxel. | Jul 2014 | Recommended with restriction | input received |
| abiraterone Initial and continuing treatment of metastatic castration-resistant prostate cancer in patients with disease progression following docetaxel treatment, in… | Jul 2012 | Rejected | unclear |
| abiraterone Initial and continuing treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients whose disease progression has occurred following… | Mar 2012 | Not recommended | unclear |
| abiraterone Initial and continuing treatment of metastatic advanced prostate cancer (castration resistant prostate cancer) in patients whose disease progression has… | Nov 2012 | Not recommended | unclear |
| abiraterone Treatment of castration resistant metastatic carcinoma of the prostate in patients who have failed treatment with docetaxel, in combination with prednisone or… | Nov 2012 | Recommended with restriction | no section in document |
| abiraterone Treatment of metastatic castration-resistant prostate cancer in patients whose disease has progressed following docetaxel chemotherapy, in combination with… | Nov 2011 | Not recommended | no section in document |
| cabazitaxel Treatment of hormone refractory metastatic carcinoma of the prostate in patients previously treated with a docetaxel-containing regimen. | Nov 2011 | Not recommended | unclear |
| cabazitaxel Treatment of hormone refractory metastatic carcinoma of the prostate in patients previously treated with a docetaxel-containing regimen. | Nov 2011 | Not recommended | unclear |
| docetaxel Treatment of androgen independent (hormone refractory) metastatic carcinoma of the prostate in patients with a Karnofsky performance-status score of at least… | Jul 2007 | Recommended with restriction | no section in document |
| docetaxel Treatment of androgen independent (hormone refractory) prostate cancer in patients with a Karnofsky performance-status score of at least 60%, used as… | Jul 2007 | Recommended with restriction | no section in document |
| docetaxel Treatment of androgen independent (hormone refractory) prostate cancer. | Nov 2006 | Not recommended | no section in document |
| docetaxel Treatment of patients with androgen independent (hormone refractory) prostate cancer. | Jul 2005 | Not recommended | no section in document |
Who spoke
Medical Oncology Group · Prostate Cancer Foundation · Blue Mountains Prostate Cancer Support Group · Rare Cancers Australia · Prostate Cancer Support Group · South Eastern Prostate Cancer Support Group · Support Group · Bathurst District Prostate Cancer Support Group · District Prostate Cancer Support Group · Geelong Prostate Support Group · Bega Valley Prostate Cancer Support Group · Mens Cancer Support Group
What the PBS pays
$780M in government benefit over 2024–25, across 2,767,822 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| abiraterone acetate, enzalutamide | $213.7M |
| enzalutamide | $179.9M |
| darolutamide | $147.6M |
| olaparib | $60.9M |
| abiraterone acetate and prednisolone | $57.5M |
| abiraterone acetate and methylprednisolone | $46.3M |
| abiraterone | $33.8M |
| abiraterone acetate | $33.8M |
| docetaxel | $4.9M |
| cabazitaxel | $1.8M |
| talazoparib | $0M |
Appraised elsewhere
NICE, in England and Wales, has appraised 11 technologies for this condition, recommending 8 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| lutetium 177 vipivotide tetraxetanLutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation) | TA1179 | terminated | 2026-07 |
| niraparibNiraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) | TA1032 | terminated | 2025-01 |
| lutetium 177 vipivotide tetraxetanLutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | not recommended | 2023-11 |
| olaparibOlaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | recommended restricted | 2023-05 |
| radium 223 dichlorideRadium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | recommended restricted | 2016-09 |
| cabazitaxelCabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | recommended restricted | 2016-05 |
| abirateroneAbiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | recommended | 2016-04 |
| enzalutamideEnzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA377 | recommended | 2016-01 |
| enzalutamideEnzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen | TA316 | recommended restricted | 2014-07 |
| abirateroneAbiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | recommended restricted | 2012-06 |
| docetaxelDocetaxel for the treatment of hormone-refractory metastatic prostate cancer | TA101 | recommended restricted | 2006-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 12 of 21 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.